The North Star Asset Management Inc. invests in Haemonetics Corp. (HAE) Shares

The North Star Asset Management Inc. invests in Haemonetics Corp. (HAE) Shares

North Star Asset Management Inc. increased its position in shares of Haemonetics Corp. (NYSE:HAE) by 6.6% during the second quarter, Holdings Channel reports. The institutional investor owned 221,050 shares of the company’s stock after buying an additional 13,600 shares during the period. North Star Asset Management Inc.’s holdings in Haemonetics Corp. were worth $6,408,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Bogle Investment Management L P DE boosted its stake in shares of Haemonetics Corp. by 207.7% in the first quarter. Bogle Investment Management L P DE now owns 177,525 shares of the company’s stock valued at $6,209,000 after buying an additional 119,822 shares during the period. Wellington Management Group LLP boosted its stake in shares of Haemonetics Corp. by 5.2% in the first quarter. Wellington Management Group LLP now owns 1,959,806 shares of the company’s stock valued at $68,554,000 after buying an additional 96,380 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Haemonetics Corp. by 1,068.1% in the first quarter. Goldman Sachs Group Inc. now owns 231,128 shares of the company’s stock valued at $8,085,000 after buying an additional 211,341 shares during the period. State Street Corp boosted its stake in shares of Haemonetics Corp. by 1.1% in the first quarter. State Street Corp now owns 1,030,394 shares of the company’s stock valued at $36,042,000 after buying an additional 11,371 shares during the period. Finally, Menta Capital LLC acquired a new stake in shares of Haemonetics Corp. during the first quarter valued at about $479,000. 98.64% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Haemonetics Corp. (NYSE:HAE) traded down 4.71% during mid-day trading on Friday, reaching $34.42. 487,423 shares of the company traded hands. The company’s 50 day moving average is $36.81 and its 200 day moving average is $32.61. Haemonetics Corp. has a 52-week low of $25.98 and a 52-week high of $38.06. The stock’s market capitalization is $1.77 billion.

Haemonetics Corp. (NYSE:HAE) last issued its quarterly earnings results on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. The business had revenue of $210 million for the quarter, compared to analysts’ expectations of $205.41 million. During the same quarter in the prior year, the firm posted $0.35 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities analysts forecast that Haemonetics Corp. will post $1.44 earnings per share for the current year.

HAE has been the topic of several recent research reports. Zacks Investment Research raised shares of Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. CJS Securities cut shares of Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 target price on the stock. in a research note on Tuesday, September 20th. Sidoti cut shares of Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price on the stock. in a research note on Monday, August 15th. Jefferies Group lifted their target price on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, Barrington Research cut shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $33.00.

In other Haemonetics Corp. news, Director Ronald Merriman sold 4,337 shares of the business’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total value of $152,402.18. Following the transaction, the director now owns 22,088 shares in the company, valued at $776,172.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Simon bought 60,000 shares of the stock in a transaction on Thursday, August 4th. The stock was purchased at an average price of $35.00 per share, for a total transaction of $2,100,000.00. The disclosure for this purchase can be found here. Insiders own 1.50% of the company’s stock.

Haemonetics Corp. Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Related posts

Leave a Comment